Literature DB >> 22199020

Resistant hypertension.

Robert H Fagard1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22199020     DOI： 10.1136/heartjnl-2011-300741

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


× No keyword cloud information.
  26 in total

1.  Prevalence of treatment-resistant hypertension after considering pseudo-resistance and morbidity: a cross-sectional study in Irish primary care.

Authors:  Peter Hayes; Monica Casey; Liam G Glynn; Gerard J Molloy; Hannah Durand; Eoin O'Brien; Eamon Dolan; John Newell; Andrew W Murphy
Journal:  Br J Gen Pract       Date:  2018-05-08       Impact factor: 5.386

2.  Prevalence and Comorbidities of Resistant Hypertension: A Collaborative Population-Based Observational Study.

Authors:  Simone Romano; Chiara Idolazzi; Cristiano Fava; Luigi Fondrieschi; Mario Celebrano; Pietro Delva; Lorella Branz; Angela Donato; Andrea Dalbeni; Pietro Minuz
Journal:  High Blood Press Cardiovasc Prev       Date:  2018-06-29

Review 3.  Coronary heart disease risk factors and outcomes in the twenty-first century: findings from the REasons for Geographic and Racial Differences in Stroke (REGARDS) Study.

Authors:  Hemal Bhatt; Monika Safford; Stephen Glasser
Journal:  Curr Hypertens Rep       Date:  2015-04       Impact factor: 5.369

Review 4.  Around-the-clock ambulatory blood pressure monitoring is required to properly diagnose resistant hypertension and assess associated vascular risk.

Authors:  Ramón C Hermida; Diana E Ayala; María T Ríos; José R Fernández; Artemio Mojón; Michael H Smolensky
Journal:  Curr Hypertens Rep       Date:  2014-07       Impact factor: 5.369

5.  Therapeutic drug monitoring-guided definition of adherence profiles in resistant hypertension and identification of predictors of poor adherence.

Authors:  Valeria Avataneo; Amedeo De Nicolò; Franco Rabbia; Elisa Perlo; Jacopo Burrello; Elena Berra; Marco Pappaccogli; Jessica Cusato; Antonio D'Avolio; Giovanni Di Perri; Franco Veglio
Journal:  Br J Clin Pharmacol       Date:  2018-08-15       Impact factor: 4.335

Review 6.  Should All Patients with Resistant Hypertension Receive Spironolactone?

Authors:  Ján Rosa; Tomáš Zelinka; Ondřej Petrák; Branislav Štrauch; Robert Holaj; Jiří Widimský
Journal:  Curr Hypertens Rep       Date:  2016-11       Impact factor: 5.369

7.  Inhibition of STAT3 activation mediated by toll-like receptor 4 attenuates angiotensin II-induced renal fibrosis and dysfunction.

Authors:  Zheng Xu; Chunpeng Zou; Weihui Yu; Sujing Xu; Lan Huang; Zia Khan; Jingying Wang; Guang Liang; Yi Wang
Journal:  Br J Pharmacol       Date:  2019-05-11       Impact factor: 8.739

8.  Structural insights into aldosterone synthase substrate specificity and targeted inhibition.

Authors:  Natallia Strushkevich; Andrei A Gilep; Limin Shen; Cheryl H Arrowsmith; Aled M Edwards; Sergey A Usanov; Hee-Won Park
Journal:  Mol Endocrinol       Date:  2013-01-15

9.  Healthy lifestyle factors and risk of cardiovascular events and mortality in treatment-resistant hypertension: the Reasons for Geographic and Racial Differences in Stroke study.

Authors:  Keith M Diaz; John N Booth; David A Calhoun; Marguerite R Irvin; George Howard; Monika M Safford; Paul Muntner; Daichi Shimbo
Journal:  Hypertension       Date:  2014-06-09       Impact factor: 10.190

10.  The contributions of unhealthy lifestyle factors to apparent resistant hypertension: findings from the Reasons for Geographic And Racial Differences in Stroke (REGARDS) study.

Authors:  Daichi Shimbo; Emily B Levitan; John N Booth; David A Calhoun; Suzanne E Judd; Daniel T Lackland; Monika M Safford; Suzanne Oparil; Paul Muntner
Journal:  J Hypertens       Date:  2013-02       Impact factor: 4.844
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.